The ALTTO Breast Cancer Trial
ALTTO: Optimizing Targeted Therapy for HER2 Breast Cancer
The Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study, or ALTTO, is an international phase III clinical trial of two targeted therapies for HER2-positive breast cancer. HER2 is expressed at high levels in up to 25 percent of all breast cancers. Tumors that overproduce HER2 are generally more aggressive and more likely to recur than those that do not.
The medications being tested in ALTTO, lapatinib (Tykerb®) and trastuzumab (Herceptin®), target HER2 in different ways. Researchers sought to find out whether one drug is better than the other at helping women live longer without a recurrence of their disease, or if the two drugs work better together.
The ALTTO study enrolled 8,000 participants in 44 countries. Women with HER2-positive breast cancer whose tumors had been completely removed by surgery were eligible to join. (See a summary of the ALTTO protocol.)
On September 9, 2011, the leadership of ALTTO announced that the lapatinib only arm of the trial was being discontinued. The discontinuation was based on the Independent Data Monitoring Committee’s review of efficacy in the trial, which was triggered after a prespecified number of events was reached, as outlined in the study’s protocol. For more information on this modification, go to the GlaxoSmithKline press release at http://us.gsk.com/html/media-news/pressreleases/2011/2011-pressrelease-614856.htm and the ALTTO trial website at http://alttotrials.com/patients.php.
On June 1, 2014, ALTTO investigators presented findings of the study at the American Society of Clinical Oncology (ASCO) annual meeting.
ALTTO is sponsored by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and GlaxoSmithKline, the maker of lapatinib, and is being coordinated by North American Breast Cancer Groups (NABCG), based in the United States, and the Breast International Group (BIG) in Brussels, Belgium.
The ALTTO trial represents a new level of international cooperation in the advancement of cancer care. ALTTO is one of the first global initiatives in which two large academic breast cancer research networks covering different parts of the world have jointly developed a study in which all care and data collection are standardized, regardless of where patients are treated.
About the Trial
Study of targeted therapies for breast cancer established model for global clinical trials
(Updated: June 1, 2014) - Two targeted medications designed to treat an aggressive form of breast cancer were tested in a study that involved 8,000 participants in 44 countries. While the purpose of this trial was to enable researchers to determine whether dual targeted treatment of early stage HER2-positive breast cancer was better than using a single agent against HER2-positive disease, results of this trial did not show a benefit for women taking the drug combination of trastuzumab or lapatinib. The trial however, did provide a new model for global cancer research and collaboration.
Targeted Agents Active Against HER2-positive Breast Cancer: Questions and Answers
(Updated: June 1, 2014) - ALTTO was a clinical trial designed to determine whether the combination of the monoclonal antibody trastuzumab (Herceptin) and the drug lapatinib (Tykerb) was more effective in treating HER2/ErbB2-positive breast cancer when combined with chemotherapy than either agent alone. Results from ALTTO did not show additional benefit from combining lapatinib and trastuzumab compared with trastuzumab treatment alone.
Targeted Cancer Therapies
(Reviewed: April 25, 2014) - A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival.
This page contains brief information about lapatinib ditosylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
This page contains brief information about trastuzumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Adjuvant and Neoadjuvant Therapy for Breast Cancer
(Reviewed: June 16, 2009) - A fact sheet that explains different types of adjuvant therapy (treatment given after primary therapy to increase the chance of long-term survival) and neoadjuvant therapy (treatment given before primary therapy). Discusses side effects, risks, and benefits of adjuvant and neoadjuvant therapy for breast cancer.
Molecular Targets in Cancer Therapy
The past two decades of biomedical research have yielded an enormous amount of information about the molecular events that take place during the development of cancer.